FDA Inspection 1284570 — Coherus Oncology, Inc.
The FDA completed an inspection of Coherus Oncology, Inc. on September 9, 2025 in Redwood City, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 9, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Redwood City, CA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)